Drug Sales Trends for SKLICE

Annual Sales Revenues and Units Sold for SKLICE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
SKLICE			2021
SKLICE			2020
SKLICE			2019
SKLICE			2018

Global Lice Treatment Market: A Comprehensive Analysis of Sklice (Ivermectin Lotion)

Introduction

The global lice treatment market is experiencing significant growth, driven by increasing prevalence, improved access to treatments, and heightened consumer awareness. One of the key players in this market is Sklice, an ivermectin lotion developed by Arbor Pharmaceuticals. Here, we delve into the market analysis and sales projections for Sklice.

Market Size and Growth Projections

The global lice treatment market was valued at US$ 1,049.8 million in 2022 and is projected to reach US$ 1,583.4 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.00% during the forecast period[1][5].

Product Type Segmentation

The market is segmented into Over-The-Counter (OTC) medication and prescription medication. The OTC medication segment, which includes Sklice, is expected to hold a dominant position due to its minimal side effects and ease of access. Sklice, in particular, has benefited from its Rx-to-OTC switch approved by the FDA in October 2020, allowing for nonprescription use[1][3][5].

Distribution Channels

The market is segmented into hospitals and clinics, retail pharmacies, and other distribution channels. Retail pharmacies are the major contributors to the market, and this segment is expected to dominate during the forecast period. The ease of accessing OTC medications like Sklice from retail pharmacies has been a significant factor in this growth, especially during the COVID-19 pandemic when more people opted for retail pharmacies over hospitals for routine treatments[1][3][5].

Geographic Segmentation

North America is the largest market for lice treatments, including Sklice. However, the Asia Pacific region is expected to be the fastest-growing market during the forecast period. The global reach of Sklice, particularly through licensing agreements such as the one with KAKEN PHARMACEUTICAL CO., LTD. for Japan, further expands its market potential[1][3].

Impact of COVID-19

The COVID-19 pandemic had a positive impact on the global lice treatment market. There was an increase in ivermectin dispensing from outpatient retail pharmacies in the U.S., with prescriptions peaking at 39,000 in the week ending January 8, 2021, compared to an average of 3,600 prescriptions per week pre-pandemic. This surge in demand was partly due to increased awareness and the convenience of accessing treatments from retail pharmacies[1].

Key Drivers of Market Growth

Several factors are driving the growth of the lice treatment market, including:

• Increasing Prevalence: Lice infestations are common, affecting millions globally.
• Easy Availability: The Rx-to-OTC switch for Sklice has made it easier for consumers to access the treatment without a prescription.
• Heightened Awareness: Increased awareness among the population about lice treatments has driven market expansion[5].

Sklice (Ivermectin Lotion) Specifics

Sklice, a 0.5% ivermectin lotion, was initially approved by the FDA in February 2012 for prescription use and later approved for OTC use in October 2020. This lotion is effective for treating head lice infestations in patients six months and older. The licensing agreement between KAKEN PHARMACEUTICAL CO., LTD. and Arbor Pharmaceuticals has also facilitated its commercialization in Japan[1][3][5].

Sales Projections

Given the market trends and the specific advantages of Sklice, sales projections are optimistic. The OTC segment, driven by products like Sklice, is expected to continue dominating the market. With a CAGR of 6.00%, the global lice treatment market is poised to reach US$ 1,583.4 million by 2030. Sklice, being a key player in this segment, is likely to contribute significantly to these projections[1][5].

Competitive Landscape

The global lice treatment market includes several key players such as Fleming Medical Ltd, ParaPRO, LLC, Prestige Consumer Healthcare Inc., Omega Pharma, Alliance Pharma PLC, and Johnson & Johnson Private Limited, among others. Arbor Pharmaceuticals, the developer of Sklice, has a strong position in the market due to its innovative product and strategic licensing agreements[1].

Conclusion

The global lice treatment market, particularly the segment involving Sklice, is on a trajectory of significant growth. Driven by factors such as increased prevalence, easy availability of OTC medications, and heightened consumer awareness, Sklice is well-positioned to continue its market dominance.

Key Takeaways

• The global lice treatment market is projected to reach US$ 1,583.4 million by 2030.
• Sklice, an ivermectin lotion, has benefited from its Rx-to-OTC switch and is a dominant player in the OTC segment.
• Retail pharmacies are the primary distribution channels for lice treatments.
• North America is the largest market, but the Asia Pacific region is expected to be the fastest-growing.
• The COVID-19 pandemic positively impacted the market by increasing demand for lice treatments.

FAQs

Q: What is the current market size of the global lice treatment market? A: The global lice treatment market was valued at US$ 1,049.8 million in 2022[1].

Q: What is the expected CAGR of the global lice treatment market? A: The market is expected to grow at a CAGR of 6.00% during the forecast period from 2023 to 2030[1].

Q: What is the significance of the Rx-to-OTC switch for Sklice? A: The Rx-to-OTC switch approved by the FDA in October 2020 allows for nonprescription use of Sklice, making it easier for consumers to access the treatment[1][3][5].

Q: Which distribution channel dominates the lice treatment market? A: Retail pharmacies are the major contributors to the market and are expected to dominate during the forecast period[1][3][5].

Q: How has the COVID-19 pandemic affected the lice treatment market? A: The pandemic had a positive impact, with an increase in ivermectin dispensing from outpatient retail pharmacies in the U.S.[1].

Sources

1. Coherent Market Insights: Lice Treatment Market - Share, Size and Industry Analysis.
2. ASPE: COST OF GENERIC DRUG DEVELOPMENT AND APPROVAL FINAL.
3. Straits Research: Lice Treatment Market Size, Share and Forecast to 2031.
4. LEO Pharma: 2024 Solid start to the year.
5. GlobeNewswire: OTC and Prescription Solutions Fuel Growth in the Global Lice Treatment Market With Key Players Leading the Way.